Group 1 - The company has approved a share repurchase plan to buy back its own A-shares, with a maximum price of RMB 62.76 per share and a total repurchase fund ranging from RMB 150 million to RMB 300 million, to be executed within 12 months [1][2] - The purpose of the repurchased shares has been adjusted from employee stock ownership plans or equity incentives to cancellation and reduction of registered capital [2] - A total of 3,540,021 shares have been repurchased, accounting for 0.5890% of the company's total share capital, with a total expenditure of approximately RMB 150.07 million [2] Group 2 - Following the cancellation of the repurchased shares, the company's total share capital will decrease from 601,065,290 shares to 597,525,269 shares, and registered capital will reduce from RMB 601,065,290 to RMB 597,525,269 [3] - Creditors are notified that they have 30 days from receiving the notice or 45 days from the announcement date to claim their debts or request guarantees [3][4] - Required documents for creditors to declare their claims include contracts, agreements, and other proof of debt, along with identification and authorization documents if applicable [3]

Core Points - The company announced a share repurchase plan with a total expected amount between RMB 150 million and RMB 300 million, with a maximum repurchase price of RMB 62.76 per share [1][2] - The actual number of shares repurchased is 3,540,021, representing 0.5890% of the total share capital, with a total expenditure of approximately RMB 150.07 million [3][4] - The purpose of the repurchased shares has been adjusted from employee stock ownership plans to cancellation and reduction of registered capital [2][3] Repurchase Plan Details - The repurchase period is from September 5, 2024, to September 4, 2025, and the company has complied with the regulations during the repurchase process [3][4] - The repurchase was conducted through centralized bidding, with the highest transaction price at RMB 45.14 per share and the lowest at RMB 37.65 per share, resulting in an average price of RMB 42.39 per share [3][4] - The company plans to cancel the repurchased shares on September 8, 2025, and will notify creditors regarding the capital reduction [6][7] Share Capital Changes - Before the repurchase, the total number of shares was 601,065,290, and after the cancellation of the repurchased shares, it will be reduced to 597,525,269 [6] - The repurchased shares will be canceled, leading to a decrease in the company's registered capital, which aligns with the long-term interests of the company and its investors [3][7]

Group 1 - Gannee Pharmaceutical has completed a share buyback, acquiring a total of 3.540021 million shares, which represents 0.589% of the company's total share capital [1] - The highest transaction price during the buyback was 45.14 CNY per share, while the lowest was 37.65 CNY per share, with an average buyback price of 42.39 CNY per share [1] - The total amount spent on the buyback was approximately 150 million CNY [1] Group 2 - For the year 2024, Gannee Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - The current market capitalization of Gannee Pharmaceutical is 45 billion CNY [2]

证券代码：603087 证券简称：甘李药业 公告编号：2025-064 甘李药业股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/6 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2024 9 9 4 | 5 | 日~2025 | 年 | 日 | | 预计回购金额 | 15,000万元~30,000万元 | | | | | | 回购价格上限 | 62.76元/股 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 354.0021万股 | | | | | | 实际回购股数占总股本比例 | 0.5890% | | | | | | 实际回购金额 | 15,006.9654万元 | | | | | | 实际回购价 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-065 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次回购股份注销并减少注册资本的情况暨通知债权人的原因 中竞价交易方式实施回购股份 3,540,021 股，占公司总股本的比例为 0.5890%， 成交最高价为 45.14 元/股，成交最低价为 37.65 元/股，已支付的资金总额约为人 民币 15,006.9654 万元（不含交易费用），公司本次回购方案已实施完毕。具体内 容详见公司于 2025 年 9 月 8 日在上海证券交易所披露的《关于股份回购实施结 果暨股份变动的公告》（公告编号：2025-064）。 二、需债权人知晓的相关信息 上述回购股份 3,540,021 股注销完成后，公司总股本将由 601,065,290 股减少 至 597,525,269 股，注册资本将由 601,065,290 元减少至 597,525,269 元（鉴于公 司前次回购注销部分限制性股票并减少注册资本尚未完成，公司总股本暂按 601,065,290 股计算，最终 ...

Core Viewpoint - 甘李药业 has shown significant growth in stock price and financial performance, indicating strong market interest and operational success [1][2]. Financial Performance - As of June 30, 甘李药业 reported a revenue of 2.067 billion yuan, representing a year-on-year increase of 57.18% [2]. - The net profit attributable to shareholders reached 604 million yuan, marking a substantial growth of 101.96% compared to the previous year [2]. - Cumulatively, the company has distributed 1.612 billion yuan in dividends since its A-share listing, with 1.018 billion yuan distributed over the last three years [3]. Stock Performance - The stock price of 甘李药业 increased by 69.72% year-to-date, with a recent 5-day increase of 0.32%, a 20-day increase of 19.00%, and a 60-day increase of 31.04% [1]. - The stock was trading at 73.16 yuan per share, with a market capitalization of 43.974 billion yuan as of September 5 [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 77,300, up by 3.08% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.99% to 7,165 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 174,800 shares, and new entrants like Innovation Drug and Southern Alpha Mixed A [3].

Group 1 - The biopharmaceutical ETF (159859) has shown strong performance, rising 1.16% with a trading volume exceeding 94 million yuan, making it the top performer among its peers [1] - The ETF has seen a net inflow of over 61 million yuan over the past three trading days, indicating strong investor interest [1] - The ETF closely tracks the National Index of Biopharmaceuticals (399441.SZ), which covers various sectors including innovative drugs, CXO, vaccines, and blood products [1] Group 2 - The innovative drug ETF Tianhong (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and is the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index [2] - The Tianhong ETF has also experienced a net inflow of over 64 million yuan over the past three trading days, reflecting positive market sentiment [2] - A recent meeting emphasized the need for comprehensive reforms in drug regulation and innovation, which could positively impact the pharmaceutical industry [2] Group 3 - Overall, the market may face short-term fluctuations, but there are signs of capital rotation, with many undervalued stocks beginning to rebound [3] - The expectation of interest rate cuts and economic recovery may lead to a focus on cyclical sectors in the future [3]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.14% on August 28, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Xizang Pharmaceutical (600211) with a closing price of 48.83, up 9.00% and a trading volume of 375,100 shares, totaling 1.83 billion yuan [1] - Wendi Pharmaceutical (688488) closed at 17.78, up 5.39% with a trading volume of 137,700 shares, totaling 235 million yuan [1] - Rili Pharmaceutical (603087) closed at 71.48, up 4.40% with a trading volume of 221,400 shares, totaling 1.54 billion yuan [1] - Conversely, Kanghong Pharmaceutical (002773) saw a decline of 3.36%, closing at 39.36 with a trading volume of 173,800 shares, totaling 676 million yuan [2] - Other notable decliners included: - Bohui Innovation (300318) down 3.23% to 5.99 [2] - Jinzhenke (688670) down 3.14% to 15.40 [2] Capital Flow - The biopharmaceutical sector experienced a net outflow of 888 million yuan from institutional investors, while retail investors saw a net inflow of 941 million yuan [2] - The capital flow for specific stocks showed: - Xizang Pharmaceutical had a net inflow of 2.26 billion yuan from institutional investors, while retail investors had a net outflow of 547.24 million yuan [3] - Ganli Pharmaceutical saw a net inflow of 79.74 million yuan from institutional investors, with retail investors experiencing a net outflow of 21.51 million yuan [3]

Core Insights - The Chinese biopharmaceutical industry is experiencing a surge in performance, with 69.23% of 39 innovative drug companies reporting positive net profit growth in their semi-annual reports [1] - Six companies reported over 100% year-on-year growth in net profit, indicating strong development momentum in the sector [1] Company Performance - **Kexing Pharmaceutical** achieved the highest net profit growth at 576.45%, totaling 0.80 billion yuan, focusing on antiviral, oncology, and immunology treatments [1] - **Sanno Bio** reported a 308.29% increase in net profit, reaching 0.89 billion yuan, driven by significant growth in raw material drug sales [2][3] - **Jinkai Biotechnology** saw a 123.61% increase in net profit, providing custom development services for small molecule drugs [3] - **Wuxi AppTec** and **Hengrui Medicine** also ranked among the top three companies by revenue, with 207.99 billion yuan and 157.61 billion yuan respectively [4] Industry Trends - The industry is transitioning from an "investment phase" to a "harvest phase," indicating a recovery in profitability and a moderate expansion stage [4] - Recent policy measures from the National Healthcare Security Administration aim to support high-quality development in innovative drug research and market application [4] - Analysts predict that the innovative drug sector will continue to thrive, driven by efficiency and cost advantages in drug development [5]

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by a senior executive of Ganli Pharmaceutical, confirming that the reduction was executed as planned without any discrepancies. Group 1: Executive Shareholding and Reduction Plan - Prior to the reduction, the senior executive, Sun Cheng, held 530,200 shares, representing 0.088% of the company's total share capital [1] - The reduction plan disclosed on July 5, 2025, indicated that Sun Cheng intended to reduce his holdings by up to 20,000 shares, which is 3.77% of his total shares and 0.0033% of the company's total share capital [1] - On August 19, 2025, Sun Cheng successfully reduced his holdings by 20,000 shares, equating to 0.0033% of the company's total share capital, thus completing the reduction plan [1] Group 2: Implementation Results - The reduction plan was fully implemented as per the disclosed schedule [1] - The actual reduction matched the previously disclosed plan, confirming that the minimum reduction quantity was achieved [1] - There was no early termination of the reduction plan, indicating adherence to the original timeline [1]